San Francisco, California
London, United Kingdom
Oxford Biotech is pleased to announce our next major event:
The Future of Drug Discovery: Open Innovation
The event will feature talks from a range of key speakers, followed by panel discussions and questions from the audience. The evening will conclude with a drinks reception, an opportunity for networking and further discussion. The event is free to attend, and open to all OB members.
Confirmed speakers so far include:
Our event will finish with an announcement that will make exactly that possible, so join us on December 4th!
Who should attend?
The event will be of interest to industry professionals and academics alike, especially those with an interest in the health and life sciences. The Open Innovation model will be explored in detail and is applicable to entrepreneurial start-ups and large established organisations alike. OB Events are well-attended and represent a convenient way to meet like-minded people within, and outside of, your primary field of work. OB promotes discussion and the sharing of ideas and contributions from all backgrounds, disciplines and professions are valued. Attendees must be OB members (membership is free and enables you to take advantage of our many benefits, join OB now for free: www.OxfordBiotech.org )
What are my transport/parking options getting to the event?
Parking is limited in central Oxford, however the city does provide convenient park & ride options. Additionally, Oxford train station is only a 10-minute walk from the University area.
Where can I contact the organiser with any questions?
You can find contact details on our website: www.OxfordBiotech.com
When & Where
Panacea Innovation (formerly Oxford Biotech) is an umbrella underneath which novel initiatives are introduced to mine for “undervalued assets” in the Academia/Industry/Investment triple-helix and give rise to high-impact assets, whenever and wherever.
Our mission is to change the way the world does science, for the betterment of humankind, by establishing vehicles that aim to maximize life and health sciences translation whilst providing outstanding revenues to our partners.
Panacea Innovation initiatives are broad ranging. From academia, where funding and credit for scientists and clinicians can be controlled by publishing lots of low- impact papers or speaking at conferences in a cycle that seems underperforming, to industry where the declining R&D productivity has raised doubts about the sustainability of its renowned financial returns, to venture capital where investors still need a better established deal flow rather than looking for the Nash equilibrium.